MAVORIC trial could lead to new treatment for dermatology patients
13 June 2019
The skin lymphoma team at University Hospitals Birmingham NHS Foundation Trust have worked alongside international colleagues on the largest clinical trial of its kind.
The MAVORIC trial, which compared a new treatment for two rare forms of skin cancer with the current standard treatment, recruited 370 patients across more than 60 centres worldwide.
The trial found the new treatment, mogamulizumab, led to survival rates doubling from three months to seven months for patients with mycosis fungoides and Sezary syndrome, two rare forms of skin cancer Cutaneous T-cell lymphoma (CTCL) .
Prof Julia Scarisbrick, UHB Consultant Dermatologist, said: “The results from the MAVORIC trial have been promising, and we are hoping that NICE will soon approve mogamulizumab for use across NHS hospitals.
“With an average progression-free survival rate of 7.6 months, mogamulizumab was shown to be more than twice as effective as vorinostat in treating mycosis fungoides or Sezary syndrome, in cases where at least one previous treatment had failed.
“For decades, these forms of CTCL have been difficult to treat, so the approval of mogamulizumab would fill a clear unmet need.”
Mycosis fungoides is the most common form of CTCL, representing over half of all cases. Sezary syndrome is a more aggressive, rarer form of CTCL, which is found in less than 5% of cases.
Mogamulizumab is an antibody that targets a receptor in the body that is found in a number of skin cancer conditions, including mycosis fungoides and Sezary syndrome.
MAVORIC was the first clinical trial to focus on symptoms. The aim was to find out whether mogamulizumab prevented patient’s symptoms from worsening.
The findings from MAVORIC were published in the LANCET last year, with a decision on NICE approval for mogamulizumab expected later this year.